Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct‐acting antiviral treatment
暂无分享,去创建一个
D. Bernstein | J. Kort | M. Sulkowski | S. Gordon | Sandra S. Lovell | F. Mensa | M. Fried | F. Poordad | T. Ng | S. Flamm | C. Landis | Armen Asatryan | R. Reindollar | F. Felizarta | Ran Liu | Chih‐Wei Lin | A. Asatryan
[1] R. Kamel. AASLD 2016 Recommendations for Testing, Managing, and Treating Hepatitis C , 2017 .
[2] Liangjun Lu,et al. In Vitro Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS5A Inhibitor Pibrentasvir , 2017, Antimicrobial Agents and Chemotherapy.
[3] T. Hassanein,et al. High Efficacy of ABT-493 and ABT-530 Treatment in Patients With HCV Genotype 1 or 3 Infection and Compensated Cirrhosis. , 2016, Gastroenterology.
[4] M. Fried,et al. Treatment options of patients with chronic hepatitis C who have failed prior therapy , 2016, Clinical liver disease.
[5] T. Asselah,et al. Direct‐acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN‐free treatment and future perspectives , 2016, Liver international : official journal of the International Association for the Study of the Liver.
[6] D. Felmlee,et al. Mechanisms of Hepatitis C Viral Resistance to Direct Acting Antivirals , 2015, Viruses.
[7] S. Naggie,et al. Successes and Challenges on the Road to Cure Hepatitis C , 2015, PLoS pathogens.
[8] K. Reddy,et al. GrazoprevirElbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection , 2015, Annals of Internal Medicine.
[9] T. Pilot‐Matias,et al. O057 : Long-term follow-up of treatment-emergent resistance-associated variants in NS3, NS5A and NS5B with paritaprevir/r-, ombitasvir- and dasabuvir-based regimens , 2015 .
[10] A. Mangia,et al. O059 : Long-term persistence of HCV NS5A variants after treatment with NS5A inhibitor ledipasvir , 2015 .
[11] P. Pang,et al. O005 : Retreatment of patients who failed 8 or 12 weeks of ledipasvir/sofosbuvir-based regimens with ledipasvir/sofosbuvir for 24 weeks , 2015 .
[12] H. Mo,et al. P0773 : The prevalence and the effect of HCV NS5A resistance associated variants in subjects with compensated cirrhosis treated with ledipasvir/sofosbuvir +/- RBV , 2015 .
[13] H. Razavi,et al. Global epidemiology and genotype distribution of the hepatitis C virus infection. , 2014, Journal of hepatology.
[14] Alvaro Mena,et al. Update on hepatitis C virus resistance to direct-acting antiviral agents. , 2014, Antiviral research.
[15] A. Flaxman,et al. Global Distribution and Prevalence of Hepatitis C Virus Genotypes , 2014, Hepatology.
[16] Thomas Berg,et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. , 2014, The New England journal of medicine.
[17] R. Marinho,et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. , 2014, The New England journal of medicine.
[18] J. Pawlotsky. New hepatitis C therapies: the toolbox, strategies, and challenges. , 2014, Gastroenterology.
[19] M. Manns,et al. Once‐daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment‐naïve genotype 1 hepatitis C: The randomized PILLAR study , 2013, Hepatology.
[20] Min Gao,et al. Antiviral activity and resistance of HCV NS5A replication complex inhibitors. , 2013, Current opinion in virology.
[21] A. Bruchfeld,et al. High‐dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C , 2005, Hepatology.
[22] M. Buti,et al. Grazoprevir, Elbasvir, and Ribavirin for Chronic Hepatitis C Virus Genotype 1 Infection After Failure of Pegylated Interferon and Ribavirin With an Earlier-Generation Protease Inhibitor: Final 24-Week Results From C-SALVAGE. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[23] C. Stedman,et al. Sofosbuvir/Velpatasvir in Combination with Ribavirin for 24 Weeks is Effective Retreatment for Patients who failed Prior NS5A Containing DAA Regimens: Results of the GS-US-342-1553 Study , 2016 .
[24] T. Hassanein,et al. High Efficacy and Favorable Safety of ABT-493 and ABT-530 Co-Administration for 12 Weeks in HCV Genotype 1-Infected Patients with Cirrhosis (Surveyor-I) , 2016 .